Loading...
Allena Pharmaceuticals, Inc.
ALNA•NASDAQ
HealthcareBiotechnology
$0.07
$0.002(3.16%)
Allena Pharmaceuticals, Inc. (ALNA) Stock Overview
Explore Allena Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for ALNAStats details for ALNA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALNAAnalyst Recommendations details for ALNA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.
CEO
Dr. Louis Brenner
Employees
12
Headquarters
1 Newton Executive Park Ste 202, Newton, MASSACHUSETTS
Founded
2017